TABLE 2.
Parameter type | Subgroup options |
Etiology of cardiomyopathy* | ICM |
NICM | |
ACM | |
Age* | |
Gender* | |
BMI | |
LVEF* | |
NYHA group* | |
Ventricular arrhythmia presentations* | Sustained ventricular tachycardia incessant sustained ventricular tachycardia electrical storm |
Arrhythmogenic focus anatomical intracardiac location | Based on VE exit by ECG and by the activation map of VT |
Diagnostic tools used for scar definition | CT |
MR | |
EAM | |
ECG | |
TA volume* | Endocardial electroanatomic substrate mapping area/volume in all cases; epicardial mapping area/volume in the case of 3D epicardial electroanatomic substrate mapping |
Heart volume | cc range |
Heart-to-TA volume | cc range |
Previous use of amiodaron | Y/N |
Number of previous RFA attempts* | |
Type of previous RFA attempts | endocardial |
epicardial | |
Unfeasibility to repeat RFA | Y/N |
Local recurrence of TA (same area of last RFA) | Y/N |
Previous percutaneous stellate ganglion blockade | Y/N |
TA, target area by electroanatomical mapping; BMI, body mass index; RFA, radiofrequency ablation; LVEF, left ventricle ejecting fraction; *mandatory matching factor.